Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023Business Wire • 03/02/23
Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology IndicationsBusiness Wire • 02/22/23
Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing LossBusiness Wire • 02/08/23
Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech ConferenceBusiness Wire • 11/29/22
Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular DegenerationBusiness Wire • 11/28/22
Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 11/10/22
Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022Business Wire • 11/03/22
Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium CellsBusiness Wire • 10/10/22
Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the MesaBusiness Wire • 10/04/22
Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in IsraelBusiness Wire • 10/03/22
Lineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology ConferenceBusiness Wire • 08/15/22
Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/12/22
Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 08/11/22
Lineage Cell Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022Business Wire • 08/04/22
A Quick Look At Lineage Cell Therapeutics And Its Product Development EffortsSeeking Alpha • 07/20/22
Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery TechnologyBusiness Wire • 06/02/22
Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q1 2022 Results - Earning Calls TranscriptSeeking Alpha • 05/13/22
Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 05/12/22
Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022Business Wire • 05/05/22